Kolexia
Caillot Denis Médecine interne
Caillot Denis
Médecine interne
Clinique Mutualiste Benigne Joly
Talant, France
345 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Myélome multiple Leucémies Tumeurs à plasmocytes Leucémie aigüe myéloïde Leucémie myéloïde Maladie résiduelle Tumeurs hématologiques Leucémie-lymphome lymphoblastique à précurseurs B et T Mycoses

Collaborateurs

Voir plus
Moreau Philippe
Moreau Philippe
Hôpital Hôtel-Dieu Nantes, Nantes, France
Hulin Cyrille
Hulin Cyrille
Hôpital Haut-lévêque, Pessac, France
Leleu Xavier
Leleu Xavier
Hôpital La Miletrie, Poitiers, France
Facon Thierry
Facon Thierry
Hôpital Huriez, Lille, France

Industries

Voir plus
Janssen
6 collaboration(s)
Dernière en 2023
Sanofi
5 collaboration(s)
Dernière en 2022
A+A
4 collaboration(s)
Dernière en 2021
Novartis
4 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Early CAR-T Cells expansion is associated with prolonged PFS for patients with RRMM treated with ide-cel: a retrospective monocentric study.
Transplantation and cellular therapy   06 mars 2024
Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Combination With Standard Chemotherapy During Induction and Consolidation Followed by 12 Months of Maintenance Monotherapy in Patients With Newly-diagnosed FMS-like Tyrosine 3 (FLT3) Kinase Receptor-mutated Acute Myeloid Leukemia.: An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
Essai Clinique (Novartis)   27 février 2024
Long-term outcome after autologous BCR::ABL1-negative peripheral blood stem cell transplantation in adults with Philadelphia-positive acute lymphoblastic leukemia: a comparative study.
Haematologica   30 novembre 2023
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma: BEACOPP (4 Cycles Escalated + 4 Cycles Baseline) Versus ABVD (8 Cycles) In Stage III & IV Hodgkin's Lymphoma
Essai Clinique (Organisation européenne pour la recherche et le traitement du cancer)   08 novembre 2023
Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01
65th ASH Annual Meeting Abstracts   02 novembre 2023
Multicenter Open Label Phase 2 Study of Quadruplet-Based Regimen Iskpd (isatuximab plus pomalidomide and dexamethasone with carfilzomib) in Early Relapsed or Refractory Multiple Myeloma - IFM2018-03
65th ASH Annual Meeting Abstracts   02 novembre 2023
Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05
65th ASH Annual Meeting Abstracts   02 novembre 2023
French Early Nationwide Idecabtagene Vicleucel (Ide-Cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy Experience in Patients with Relapsed/Refractory Multiple Myeloma (FENIX): Update of the IFM Study from the Descar-T Registry
65th ASH Annual Meeting Abstracts   02 novembre 2023
Oncogenetic-Driven Targeted Therapy for Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia : A French ALL-Target Observatory Report
65th ASH Annual Meeting Abstracts   02 novembre 2023
Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020
65th ASH Annual Meeting Abstracts   02 novembre 2023